The invention provides novel photolytic compounds and prodrugs, nanoparticles and compositions thereof, and methods of conducting photolysis mediated by triplet-triplet annihilation.

This invention relates generally to methods for increasing bioactivity of lunasin in liquid formulations, sonicated bioactive lunasin compositions and methods of using sonicated bioactive lunasin. More specifically, this invention relates to methods of increasing bioactivity of lunasin in liquid formulations by administering sonication. One embodiment the present invention provides a method of increasing the bioactivity of lunasin comprising: a) providing a composition comprising lunasin, b) putting said composition into solution, and c) administering sonication to the composition.

A composition having nanoparticles having lipids; a polysaccharide coating, an active agent and iron oxide. The active agent can be ciprofloxacin or fluocinolone. A method of treatment of ear disease or ear infection including the administration of a pharmaceutical formulation comprising nanoparticles and magnetically pushing or pulling the nanoparticles to a treatment site.

A composition having nanoparticles having lipids; a polysaccharide coating, an active agent and iron oxide. The active agent can be ciprofloxacin or fluocinolone. A method of treatment of ear disease or ear infection including the administration of a pharmaceutical formulation comprising nanoparticles and magnetically pushing or pulling the nanoparticles to a treatment site.

The present disclosure belongs to the field of medicines, and particularly relates to property researches of an indotricarbocyanine structure-based small molecule medicine for tumor photothermal therapy. The present disclosure is based on a large-conjugated water-soluble indotricarbocyanine dye compound developed by the applicant, and the compound can be used as a photothermal therapeutic agent, and has a potential development and application prospect. In the present disclosure, the compound is found to be an excellent tumor photothermal therapy medicine, and such use of this compound has not been found and reported at present. Through in-vitro property researches on the photothermal efficiency of this compound, a foundation is provided for clinical application of the indocyanine green-like small molecule photothermal therapeutic agent, and a basis is provided for researches of the small molecule photothermal therapeutic agent.

An improved method of promoting hair growth includes the use of one or more photosensitive curcuminoids, provided in combination with other hair growth components and preferably solubilized in bio-compatible materials to create a nano-particulate. These materials are introduced via fractional topical delivery and subsequently activated by exposure to specific wavelengths of light. This sequence results in improved hair growth in comparison to previously known methods, and the use of photosensitive curcuminoids in this manner may be employed to treat other skin disorders.

A catheter comprises an elongated carrier and a balloon carried by the carrier in sealed relation thereto. The balloon has an outer surface and is arranged to receive a fluid therein that inflates the balloon. The catheter further comprises a shock wave generator within the balloon that forms mechanical shock waves within the balloon, and a medicinal agent carried on the outer surface of the balloon. The medicinal agent is releasable from the balloon either before or in response to the shock wave.

The invention relates to a compound of formula (I) and to the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compound of formula (I) in the treatment of cancer, particularly by photodynamic therapy.

Biologically active compounds and their methods of preparation are provided that may be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of non-tumorous indications such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, otorhinolaryngology disorders, ophthalmological or urological disorders. As the compounds exhibit also toxicity against targets (tumor cells, bacteria, inflammation-related cells) without light these biologically active compounds may also be used for the light-independent treatment of such indications. Embodiments also include methods to synthesize boron dipyrromethene complex structures incorporating a substituted 2,3,5,6-tetrafluorophenyl-dipyrromethene (2,3,5,6-tetrafluorophenyldipyrrin) unit or a substituted 3-nitrophenyl-dipyrromethene (3-nitrophenyl-dipyrrin) unit. Amphiphilic compounds with increased anti-tumour and anti-bacterial efficacy are also provided. Specifically, this is achieved by substitution with bromine atoms and sugar moieties.

Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that is wholly deliverable to a patient in a single dose. The actinium-225 labeled anti-CD45 may be administered alone or in combination with additional therapeutic agents, such as other immunotherapeutics or a radiosensitizing agent, or additional therapeutic interventions, such as bone marrow transplant or adoptive cell therapies.